Cytoplasmic accumulation of sequestosome 1 (p62) is a predictor of biochemical recurrence, rapid tumor cell proliferation, and genomic instability in prostate cancer

Clinical Cancer Research

Volumn 21, Issue 15, 2015, Pages 3471-3479

  Burdelski, Christoph ^a   Reiswich, Viktor ^a   Hube Magg, Claudia ^a   Kluth, Martina ^a   Minner, Sarah ^a   Koop, Christina ^a   Graefen, Markus ^a   Heinzer, Hans ^a   Tsourlakis, Maria Christina ^a   Wittmer, Corinna ^a   Huland, Hartwig ^a   Simon, Ronald ^a   Schlomm, Thorsten ^a   Sauter, Guido ^a   Steurer, Stefan ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROSTATE SPECIFIC ANTIGEN; PROTEIN P62; TRANSCRIPTION FACTOR ERG; PTEN PROTEIN, HUMAN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; SQSTM1 PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; BIOACCUMULATION; BIOCHEMICAL RECURRENCE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CELL PROLIFERATION; CHROMOSOME 3P; CHROMOSOME 5Q; CHROMOSOME 6Q; CONTROLLED STUDY; CYTOPLASM; ERG GENE; GENE; GENE DELETION; GENE FUSION; GENE REARRANGEMENT; GENOMIC INSTABILITY; GLEASON SCORE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PREDICTION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATE CANCER; TMPRSS2 GENE; TUMOR CELL; BIOSYNTHESIS; CANCER GRADING; DISEASE FREE SURVIVAL; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; PROGNOSIS; PROSTATE TUMOR; TISSUE MICROARRAY; TUMOR RECURRENCE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; BIOMARKERS, TUMOR; CELL PROLIFERATION; DISEASE-FREE SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMIC INSTABILITY; HUMANS; MALE; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSTATIC NEOPLASMS; PTEN PHOSPHOHYDROLASE; TISSUE ARRAY ANALYSIS;

EID: 84942925503     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-0620     Document Type: Article

References (41)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012;367:203-13.
3. Thompson IM Jr, Tangen CM. Prostate cancer-uncertainty and a way forward. N Engl J Med 2012;367:270-1.
4. Manley S, Williams JA, Ding WX. Role of p62/SQSTM1 in liver physiology and pathogenesis. Exp Biol Med 2013;238:525-38.
5. Puissant A, Fenouille N, Auberger P. When autophagy meets cancer through p62/SQSTM1. Am J Cancer Res 2012;2:397-413.
6. Bjorkoy G, Lamark T, Brech A, Outzen H, Perander M, Overvatn A, et al. p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death. J Cell Biol 2005; 171:603-14.
7. Mizushima N, Levine B, Cuervo AM, Klionsky DJ. Autophagy fights disease through cellular self-digestion. Nature 2008;451:1069-75.
8. Inoue D, Suzuki T, Mitsuishi Y, Miki Y, Suzuki S, Sugawara S, et al. Accumulation of p62/SQSTM1 is associated with poor prognosis in patients with lung adenocarcinoma. Cancer Sci 2012;103:760-6.
9. Thompson HG, Harris JW, Wold BJ, Lin F, Brody JP. p62 overexpression in breast tumors and regulation by prostate-derived Ets factor in breast cancer cells. Oncogene 2003;22:2322-33.
10. Luo RZ, Yuan ZY, Li M, Xi SY, Fu J, He J. Accumulation of p62 is associated with poor prognosis in patients with triple-negative breast cancer. Onco Targets Ther 2013;6:883-8.
11. Ren SX, Shen J, Cheng AS, Lu L, Chan RL, Li ZJ, et al. FK-16 derived from the anticancer peptide LL-37 induces caspase-independent apoptosis and autophagic cell death in colon cancer cells. PLoS One 2013;8: e63641.
12. Inui T, Chano T, Takikita-Suzuki M, Nishikawa M, Yamamoto G, Okabe H. Association of p62/SQSTM1 excess and oral carcinogenesis. PLoS One 2013;8:e74398.
13. Inami Y, Waguri S, Sakamoto A, Kouno T, Nakada K, Hino O, et al. Persistent activation of Nrf2 through p62 in hepatocellular carcinoma cells. J Cell Biol 2011;193:275-84.
14. Kitamura H, Torigoe T, Asanuma H, Hisasue SI, Suzuki K, Tsukamoto T, et al. Cytosolic overexpression of p62 sequestosome 1 in neoplastic prostate tissue. Histopathol 2006;48:157-61.
15. Je EM, Yoo NJ, Lee SH. Alteration of p62/SQSTM1 expression is uncommon in gastrointestinal and prostate cancer tissues. Gut Liver 2013;7: 625-7.
16. Schlomm T, Iwers L, Kirstein P, Jessen B, Kollermann J, Minner S, et al. Clinical significance of p53 alterations in surgically treated prostate cancers. Mod Pathol 2008;21:1371-9.
17. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-7.
18. Weischenfeldt J, Simon R, Feuerbach L, Schlangen K, Weichenhan D, Minner S, et al. Integrative genomic analyses reveal androgen-driven somatic alteration landscape in early-onset prostate cancer. Cancer Cell 2013;23:159-70.
19. Minner S, Enodien M, Sirma H, Luebke AM, Krohn A, Mayer PS, et al. ERG status is unrelated to PSA recurrence inradically operated prostate cancer in the absence of antihormonal therapy. Clin Cancer Res 2011;17:5878-88.
20. Burkhardt L, Fuchs S, Krohn A, Masser S, Mader M, Kluth M, et al. CHD1 is a 5q21 tumor suppressor required for ERG rearrangementin prostate cancer. Cancer Res 2013;73:2795-805.
21. Kluth M, Hesse J, Heinl A, Krohn A, Steurer S, Sirma H, et al. Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2-ERG fusions. Mod Pathol 2013; 26:975-83.
22. Krohn A, Diedler T, Burkhardt L, Mayer PS, De Silva C, Meyer-Kornblum M, et al. Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. Am J Pathol 2012;181:401-12.
23. Krohn A, Seidel A, Burkhardt L, Bachmann F, Mader M, Grupp K, et al. Recurrent deletion of 3p13 targets multiple tumour suppressor genes and defines a distinct subgroup of aggressive ERG fusion-positive prostate cancers. J Pathol 2013;231:130-41.
24. Minner S, Jessen B, Stiedenroth L, Burandt E, Köllermann J, Mirlacher M, et al. Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer. Clin Cancer Res 2010;16:1553-60.
25. Ellis CL, Partin AW, Han M, Epstein JI. Adenocarcinoma of the prostate with Gleason score 9-10 oncore biopsy: correlation with findings at radical prostatectomy and prognosis. J Urol 2013;190:2068-73.
26. Visakorpi T, Kallioniemi OP, Heikkinen A, Koivula T, Isola J. Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. J Natl Cancer Inst 1992;84:883-7.
27. Grupp K, Habermann M, Sirma H, Simon R, Steurer S, Hube-Magg C, et al. High nuclear karyopherin alpha 2 expression is a strong and independent predictor of biochemical recurrence in prostate cancer patients treated by radical prostatectomy. Mod Pathol 2014;27:96-106.
28. Lee YH, Ko J, Joung I, Kim JH, Shin J. Immediate early response of the p62 gene encoding a non-proteasomal multiubiquitin chain binding protein. FEBS Lett 1998;438:297-300.
29. Mathew R, Karp CM, Beaudoin B, Vuong N, Chen G, Chen HY, et al. Autophagy suppresses tumorigenesis through elimination of p62. Cell 2009;137:1062-75.
30. Takamura A, Komatsu M, Hara T, Sakamoto A, Kishi C, Waguri S, et al. Autophagy-deficient mice develop multiple liver tumors. Genes Dev 2011;25:795-800.
31. Galavotti S, Bartesaghi S, Faccenda D, Shaked-Rabi M, Sanzone S, McEvoy A, et al. The autophagy-associated factors DRAM1 and p62 regulate cell migration and invasion in glioblastoma stem cells. Oncogene 2013;32: 699-712.
32. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310:644-8.
33. Clark JP, Cooper CS. ETS gene fusions in prostate cancer. Nat Rev Urol 2009;6:429-39.
34. Grupp K, Boumesli R, Tsourlakis MC, Koop C, Wilczak W, Adam M, et al. The prognostic impact of high Nijmegen breakage syndrome (NBS1) gene expression in ERG negative prostate cancers lacking PTEN deletion isdriven by KPNA2 expression. Int J Cancer 2014;135:1399-407.
35. Stumm L, Burkhardt L, Steurer S, Simon R, Adam M, Becker A, et al. Strong expression of the neuronal transcription factor FOXP2 is linked to an increased risk of early PSA recurrence in ERG fusion-negative cancers. J Clin Pathol 2013;66:563-8.
36. Grupp K, Sanader S, Sirma H, Simon R, Koop C, Prien K, et al. High lysophosphatidylcholine acyltransferase 1 expression independently predicts high risk for biochemical recurrence in prostate cancers. Mol Oncol 2013;7:1001-11.
37. Grupp K, Jedrzejewska K, Tsourlakis MC, Koop C, Wilczak W, Adam M, et al. High mitochondria content is associated with prostate cancer disease progression. Mol Cancer 2013;12:145.
38. Belaid A, Cerezo M, Chargui A, Corcelle-Termeau E, Pedeutour F, Giuliano S, et al. Autophagy plays a critical role in the degradation of active RHOA, the control of cell cytokinesis, and genomic stability. Cancer Res 2013; 73:4311-22.
39. Piekny A, Werner M, Glotzer M. Cytokinesis: welcome to the Rho zone. Trends Cell Biol 2005;15:651-8.
40. Valencia T, Kim JY, Abu-Baker S, Moscat-Pardos J, Ahn CS, Reina-Campos M, et al. Metabolic reprogramming of stromal fibroblasts through p62-mTORC1 signaling promotes inflammation and tumorigenesis. Cancer Cell 2014;26:121-35.
41. Duran A, Linares JF, Galvez AS, Wikenheiser K, Flores JM, Diaz-Meco MT, et al. The signaling adaptor p62 is an important NF-kappaB mediator in tumorigenesis. Cancer Cell 2008;13:343-54.